Rezolute, Inc.
NEWS
While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was confounded in part by behavioral factors. The FDA acknowledged the validity of this argument.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
There was plenty of clinical trial updates last week. Here’s a look.
It was a busy week for clinical trial news. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
To facilitate its goal of building an industry-leading gene therapy company focused on rare CNS diseases, Sio has made it a priority to interact with patient organizations to determine their primary objective, whether that be stability or a cure.
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.
JOBS
IN THE PRESS